Reblozyl^®▼ is reimbursed in Belgium as of August 1^st 2021 for the treatment of adult
Patients:

• with transfusion-dependent anemia due to very low, low or intermediate-risk
  (IPSS-R) myelodysplastic syndrome (MDS) with ring sideroblasts, who had an
  unsatisfactory response to or are ineligible to erythropoietin-based therapy
• with transfusion-dependent anemia associated with B-thalassemia.

The request has to be submitted via eHealth.

The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25 mg/kg
every 21 days for beta-thalassemia.

Reblozyl^®▼ treatment will stop being reimbursed if:

• there is no reduction of the transfusion burden after 9 weeks (3 cycles) at the
  maximum dose level, if the lack of response cannot be explained otherwise
  (bleeding, surgical intervention, other concomitant disease) or,
• anytime in case of unacceptable toxicities. ⁴

▼This medicinal product is subject to additional monitoring. This will allow quick
Identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. Before prescribing Reblozyl^®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.